NUK - logo
E-viri
Celotno besedilo
Recenzirano
  • Skin manifestations and cli...
    Lee, J.W.; Lee, S.R.; Kim, M.J.; Cho, S.; Youn, S.W.; Yang, M.S.; Kim, S.H.; Kang, H.R.; Kwon, O.

    Journal of the European Academy of Dermatology and Venereology, September 2022, Letnik: 36, Številka: 9
    Journal Article

    Background Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe adverse drug reaction generally accompanied by skin manifestations as the first and most frequent symptoms. However, skin manifestations and associated clinical features of DRESS have not been fully explored and evaluated. Objectives This study aimed to describe the skin manifestations of DRESS in detail and analyse their association with demographic characteristics and extra‐cutaneous clinical features. Methods We conducted this retrospective study on patients with DRESS diagnosed between September 2009 and August 2021 at three medical institutes and validated using the RegiSCAR score. Data regarding demographics, skin manifestations and clinical characteristics were retrieved through thorough chart reviews. Results Among 182 potential cases of DRESS, the validated 125 cases were analysed. A widespread rash extending over more than 50% of the body surface area was observed in 122 patients (97.6%) and typical facial oedema was experienced by 67 patients (53.6%). Polymorphous maculopapules were the most common rash morphology (106, 84.8%): specifically, exfoliative (59, 47.2%), urticarial (57, 45.6%) and purpuric forms (39, 31.2%) were common. Mucosal involvement was observed in 41 patients (32.8%). Patients with carboxamide antiepileptics (carbamazepine and oxcarbazepine) experienced more oedema (P = 0.014) and typical facial oedema than those with allopurinol (P = 0.021). The RegiSCAR score was higher in patients with purpura (P < 0.01). Conclusions Skin manifestations of DRESS exhibit a wide range of skin lesions and can vary according to the culprit drugs. Early suspicion and prompt intervention are needed to improve prognosis.